Emerging infectious diseases · 2009 · 749 citations · 29 references
Life SciencesInfectious DiseasesMicrobiologyMicrobial EvolutionMicrobial GeneticsMycologyAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyFungal EvolutionFungal GeneticsFungal InfectionsAntifungal Drug ResistanceAspergillosis TherapyAspergillus ResistanceAzole ResistanceFungal Drug ResistanceItraconazole TherapyPopulation Genetic StructureResistance In Clinical Isolates
Azole antifungals are the primary oral treatment for aspergillosis, yet resistance has been sporadically reported since 1999 and is increasingly recognized as an emerging problem that can develop during therapy. In a collection of 519 isolates, 5% were resistant to itraconazole—a rise since 2004—with 65% cross‑resistant to voriconazole and 74% to posaconazole, and genetic analysis revealed 18 Cyp51A mutations (four novel) and evidence that resistant mutants evolved from susceptible strains.
Abstract Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate was detected in 1999 in Manchester, UK. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p<0.001). Of the 34 itraconazole-resistant isolates we studied, 65% (22) were cross-resistant to voriconazole and 74% (25) were cross-resistant to posaconazole. Thirteen of 14 evaluable patients in our study had prior azole exposure; 8 infections failed therapy (progressed), and 5 failed to improve (remained stable). Eighteen amino acid alterations were found in the target enzyme, Cyp51A, 4 of which were novel. A population genetic analysis of microsatellites showed the existence of resistant mutants that evolved from originally susceptible strains, different cyp51A mutations in the same strain, and microalterations in microsatellite repeat number. Azole resistance in A. fumigatus is an emerging problem and may develop during azole therapy.
29
High resolution of human evolutionary trees with polymorphic microsatellites
A. Bowcock, Andrés Ruiz‐Linares, James Tomfohrde et al. · Nature · 1994 · 1.9K citations
Itraconazole resistance in Aspergillus fumigatus
David W. Denning, Kevin Oakley, Michael J. Anderson et al. · Antimicrobial Agents and Chemotherapy · 1997 · 505 citations · Full text
Emilia Mellado, Guillermo García‐Effrón, Laura Alcázar‐Fuoli et al. · Antimicrobial Agents and Chemotherapy · 2007 · 498 citations · Full text